Combinatorial Therapy to Induce an HIV Remission

HIV/AIDS Clinical Trial

Official title:

Combinatorial Therapy With a Therapeutic Conserved Element DNA Vaccine, MVA Vaccine Boost, TLR9 Agonist and Broadly Neutralizing Antibodies: a Proof-of-concept Study Aimed at Inducing an HIV Remission

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04357821
• Other study ID #: 18-26957
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: August 1, 2020
• Est. completion date: December 2024

Study information

• Verified date: May 2023
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).

Description:

The investigators will perform a single arm study of twenty individuals with HIV infection on effective ART. All participants will receive a combination regimen administered during ART and then undergo an analytic treatment interruption. Our strategy has five stages 1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4 2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12 3. MVA/HIV62B (MVA62B) boost at Week 20 4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses) 5. ATI with single dose of VRC07 and 10-1074 at Week 34 Follow-up off ART will occur through at least Week 46 (expected) and on or off ART (depending on outcome) through Week 86. Should this approach work, viral load would be expected to rebound in all individuals a few weeks after the bNAb levels decrease to sub-therapeutic levels. This acute rebound would be followed by a new lower viral load set-point and perhaps a long-term remission.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 11
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 67 Years

Eligibility

Key Inclusion Criteria

1. Willing and able to provide written informed consent.

2. Age =67 years at the time of enrollment for those who started treatment during early infection and <65 years for those who started treatment during chronic infection.

3. Documented HIV-1 infection.

4. On continuous antiretroviral therapy for at least 12 months without any interruptions of greater than 14 consecutive days within the last 1 year, and on a stable regimen that does not include an non-nucleoside reverse transcriptase inhibitor (NNRTI) for at least 4 weeks, without plans to modify ART during the study period.

5. Screening plasma HIV RNA levels below the level of quantification on all available determinations in past 24 months.

6. Screening CD4+ T-cell count = 500 cells/mm3. Key Exclusion Criteria

1. Subjects receiving a non-nucleoside reverse transcriptase inhibitor

2. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study

3. High-level resistance to both 10-1074 and VRC-07 as defined using the PhenoSense Neutralizing Antibody Assay (Monogram Biosciences).

4. Any history of an HIV-associated malignancy, including Kaposi's sarcoma and any type of lymphoma, or virus-associated cancers.

5. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months or for whom such therapies are expected in the subsequent 12 months.

6. CD4+ T cell nadir <350 cells/mm3 during the chronic phase of infection (beginning 6 months following the estimated infection date and confirmed on repeat testing).

7. Active hepatitis B (HBV) infection defined as positive HBV surface antigen test.

9. Active hepatitis C (HCV) infection. 10. Presence of significant abnormalities on electrocardiogram. 11. History of potential immune-mediated medical conditions. Individuals with isolated Raynaud's phenomenon or localized disease requiring topical therapy alone will not be excluded.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• HIV/AIDS

Intervention

Drug:
• Combination Intervention
IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4 IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12 MVA/HIV62B (MVA62B) boost at Week 20 single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses) ATI with single dose of VRC07 and 10-1074 at Week 34

Locations

Country	Name	City	State
United States	Zuckerberg San Francisco General Hospital, University of California San Francisco	San Francisco	California

Sponsors (8)

Lead Sponsor	Collaborator
University of California, San Francisco	amfAR, The Foundation for AIDS Research, GeoVax, Inc., Ichor Medical Systems Incorporated, International AIDS Vaccine Initiative, Mologen AG, National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants who experience a new grade 3 or greater adverse event		Week 0 through 86
Primary	Proportion of participants achieving post-treatment control.	This will be defined as: Participants who fail to show any consistent rebound above 400 copies RNA/mL between Week 12 of the ATI (when bNAb levels wane) and Week 36 of the ATI; Participants who exhibit a rebound and eventually achieve 24 weeks of virus control will be considered as having achieved post-treatment control	Week 34 through 86
Secondary	Occurrence of any unsolicited adverse events for 28 days after administration of each study agent		Week 0 through 62
Secondary	Occurrence of any serious adverse events, medically attended adverse event, and potentially immune-mediated medical condition from the time of administration of the first study injection through 12 months after administration of the final study injection		Week 0 through 86
Secondary	Occurrence of two consecutive measurements HIV RNA >200 copies/mL using conventional assays		Week 34 to 86
Secondary	Resumptions of antiretroviral therapy after treatment interruption and the events that trigger them		Week 34 to 86
Secondary	Frequency of confirmed declines (two consecutive measurements) in CD4+ T cell counts (> 50%)		Week 34 to 86
Secondary	Frequency of confirmed declines (two consecutive measurements) to below 350 cells/mm3		Week 34 to 86
Secondary	Proportion experiencing any clinically defined episode of acute retroviral syndrome		Week 34 to 86
Secondary	Magnitude of T cell responses		Week 14
Secondary	Breadth of T cell responses	The proportion of participants with at least one additional epitope response at week 14 (2 weeks after last vaccination) compared to their baseline response	Week 14